ArticleCancer reports (Hoboken, N.J.)2022

Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer.

Giacomina Megaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.